Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. - Wikidata - wikimedia - TriplyDB

Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial.

Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial.

http://www.wikidata.org/entity/Q34027442

about

Salsalate, an old, inexpensive drug with potential new indications: a review of the evidence from 3 recent studies Is the risk of cardiovascular disease altered with anti-inflammatory therapies? Insights from rheumatoid arthritis Type-2 diabetes: Current understanding and future perspectives Regulation of energy balance by inflammation: common theme in physiology and pathology Something old, something new and something very old: drugs for treating type 2 diabetes Regulation of diet-induced adipose tissue and systemic inflammation by salicylates and pioglitazone Treatment of nonalcoholic fatty liver disease: role of AMPK.The inflammatory gene pathway is not a major contributor to polycystic ovary snydrome.Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future.C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria.Salsalate ameliorates metabolic disturbances by reducing inflammation in spontaneously hypertensive rats expressing human C-reactive protein and by activating brown adipose tissue in nontransgenic controls Risk of rheumatoid arthritis in patients with type 2 diabetes: a nationwide population-based case-control study.Inhibitory G proteins and their receptors: emerging therapeutic targets for obesity and diabetes.Anti-inflammatory therapies for cardiovascular disease A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role.Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease.Inflammation, metaflammation and immunometabolic disorders.Epicardial fat thickness as cardiovascular risk factor and therapeutic target in patients with rheumatoid arthritis treated with biological and nonbiological therapies.Sustained NF-κB activation and inhibition in β-cells have minimal effects on function and islet transplant outcomes Salsalate treatment improves glycemia without altering adipose tissue in nondiabetic obese hispanics P65 inactivation in adipocytes and macrophages attenuates adipose inflammatory response in lean but not in obese mice.Prevention of age-related endothelial dysfunction by habitual aerobic exercise in healthy humans: possible role of nuclear factor κB.Nutrition and metabolic correlates of obesity and inflammation: clinical considerations.LTB4 promotes insulin resistance in obese mice by acting on macrophages, hepatocytes and myocytes.Novel protein glycan side-chain biomarker and risk of incident type 2 diabetes mellitus.Nuclear factor κB-inducing kinase activation as a mechanism of pancreatic β cell failure in obesity.Novel Agents for the Treatment of Type 2 Diabetes.Salsalate-induced changes in lipid, lipoprotein, and apoprotein concentrations in overweight or obese, insulin-resistant, nondiabetic individuals LPS-induced NFκB enhanceosome requires TonEBP/NFAT5 without DNA binding.Renal Toxicity Associated with Salsalate in Elderly Adults with Anemia Strategies and Challenges in Clinical Trials Targeting Human Aging.Effect of Treatment with Salsalate, Menhaden Oil, Combination of Salsalate and Menhaden Oil, or Resolvin D1 of C57Bl/6J Type 1 Diabetic Mouse on Neuropathic Endpoints.Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD).Macrophages, fat, and the emergence of immunometabolism.Inflammation as a Therapeutic Target for Diabetic Neuropathies.The effect of salsalate therapy on endothelial function in a broad range of subjects.The impact of salsalate treatment on serum levels of advanced glycation end products in type 2 diabetes.Differential white cell count and incident type 2 diabetes: the Insulin Resistance Atherosclerosis Study.Salsalate attenuates diet induced non-alcoholic steatohepatitis in mice by decreasing lipogenic and inflammatory processes.Regulation of hepatocyte growth factor expression by NF-κB and PPARγ in adipose tissue.

P2860

Q24562012-B2DFBF4A-654B-490A-B312-7D4C89A0C8D6 Q26746659-01FFA902-8DF9-4E97-9E33-B819A34A572C Q26801324-76F4EA07-0A7E-40CC-BC81-69BCBA76713F Q26829584-9F6CF913-782F-4108-8281-583841C475BB Q26865663-48A8D614-C758-47F2-A667-0132056C1E17 Q28537905-87761D06-3BA8-4298-804A-DBA1D9937D7E Q30248230-2F414634-F03D-4D95-9CBB-8C59F1B95D9D Q30407754-8CBEF744-57A7-4243-A3BA-081CA64AB80E Q30597265-02CED7CD-3D49-4F0B-B141-89E171DE6B56 Q33620560-9021C098-44A1-43B4-91AD-F3E6539C0F86 Q33769258-417E7B36-0832-4667-9497-589497C9CBDB Q33838440-1B42546B-DD85-49CE-B083-A2B50BC4C8FD Q33844872-82CFF25B-E1CF-4FB6-8992-15ADA3276F54 Q34137872-1EA4717C-6621-48AB-9941-9A81F33AB984 Q34389286-2B35FC1F-EA08-412A-9A25-D37594237A64 Q34444895-7B0701D9-9BE4-47D6-B350-15A0F14CB272 Q34550852-5F8E3E23-73D8-48A8-AE13-563DBA74B857 Q34773899-512B6C71-05A2-4835-A0C0-EF775B6F4CFC Q35035258-6EF0E3C7-08ED-4ACB-A446-D9B862C888AA Q35122399-42F89B1E-01A1-4BA0-A500-BBB3A2051B2D Q35178548-A347F8EE-B344-4A19-B065-AC3D119C28B7 Q35534914-13F02DFE-F595-4E59-B355-5AEDCEBE184F Q35540750-2795616D-82CE-4849-9274-CF06AF67843E Q35600641-6E5102DD-46DB-4EDA-9C17-A0843C7159E4 Q35637841-A763A84B-6A6B-48E6-841F-B6BEA3B23567 Q35894344-70BE66BD-52CA-4B1C-9211-21C1A20CF445 Q35910421-C28B9BC9-9964-41A6-B535-DCDE9C25F2CB Q36124070-A783B984-B056-4561-9E41-751AEBB7404D Q36841546-FA057B3C-0167-4D7B-A753-E483AC19432C Q36890786-1307D2A8-5635-4652-9965-89E89202F3CB Q37322080-12FBC1BA-AC0C-4D84-945A-781BA783D984 Q37330126-E1B9DCFF-6D14-48BF-95EA-AE56AE75F358 Q37331296-AD7C2DFB-99EB-4742-8435-D03D75A2878F Q37384085-26DCFF2E-CE3F-4AAE-86E1-A80282256E2A Q37450547-18F3A98C-6AFF-4E10-8A2E-E8E3DB4CD50F Q37648486-A9A3400C-E6FA-45FC-B782-E986C3E700CF Q37660885-C353574B-CEFA-4F7A-A6A0-850CF93C8E9C Q37672638-19FF2A00-1E0A-4C76-9FF8-9335D0CE0DDF Q37686096-3F494003-E9AB-40C9-B761-01A1FE4FF4FE Q37707637-36A2D1AE-EB8C-475C-BD9F-E9C6681987FB

P2860

Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial.

http://www.wikidata.org/entity/Q34027442

description

2013 nî lūn-bûn

@nan

2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial.

@ast

Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial.

@en

Salicylate

@nl

type

label

Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial.

@ast

Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial.

@en

Salicylate

@nl

prefLabel

Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial.

@ast

Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial.

@en

Salicylate

@nl

P1433

Q34027442-FF60B333-E0C6-4BFB-A33D-4283DC8783C0

P1476

Q34027442-2ED0B6B6-C764-49E5-A897-61E1F10F9A08

P2093

Q34027442-386A7966-526F-41FA-A4AE-9218C024BB4A

Q34027442-433657EB-B6D5-4C89-8328-CB9E25BC0EB8

Q34027442-8CA9B320-336E-412E-81DB-C3F8E9735F5E

Q34027442-C207D8A2-78A5-4B3E-864E-46E0A69022A3

Q34027442-C59800F4-324E-43BF-A45C-499648D057EA

Q34027442-E2E2C8F6-A2DB-4350-A3F2-9940369AAB18

Q34027442-E7B31E88-3D35-4219-B258-FD83B8165179

P2860

Q34027442-085FEA8E-5195-49F8-A1C0-DADE2C8DC66E

Q34027442-096C177F-D743-444F-AD9F-87BDFD87D145

Q34027442-09B4D2EC-2F16-4BCA-B396-96FB1C57C866

Q34027442-0EC47603-F5F5-4314-A1D3-6DBDB926D200

Q34027442-20B7D5AC-A664-4D0F-8F6A-AF69B0D2DF38

Q34027442-25260395-A4EC-4274-B2D9-64EBF3F2E9FB

Q34027442-36FDFC99-1832-4108-80C4-51BCEA256C3B

Q34027442-408E17D3-E102-4D4C-9784-FCB845C9D014

Q34027442-49C544FD-C2F9-4E6F-AD8E-633B5E358D11

Q34027442-52535FD2-2DDE-4021-8708-76949550EB34

P304

Q34027442-786ECB17-983A-4FB4-AD19-89B24B2DE646

P31

Q34027442-54D4828D-CCFC-4112-A8DB-6172BC117A72

P356

Q34027442-F949927E-0022-474C-9F08-753E6696193B

P407

Q34027442-DCA5E5A5-A58D-44A9-BEBC-C2AD4299BEFF

P433

Q34027442-334BCE1B-57C5-4DEA-90DF-B97D79EAFB65

P478

Q34027442-BD48F9E1-BEC2-419E-B0A3-F1FAE9AEFC11

P50

Q34027442-F549AEAC-07AE-48EE-BD09-AFB19FC0B815

P577

Q34027442-543ED600-29EE-4D41-8023-5469F308B090

P698

Q34027442-907BB03D-E965-4C54-8BFE-3666BD2CEE7D

P921

Q34027442-3D83B81B-505A-45D6-BE8A-B36895DD04C3

Q34027442-EFE66C8C-8B49-4440-84EE-3B91545EF501

P932

Q34027442-5C241CDF-11E2-4CF9-B45C-5679483EB5AD

P356

0003-4819-159-1-201307020-00003

P1433

Annals of Internal Medicine

P1476

Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial.

@en

P2093

Kathleen A Jablonski

http://www.w3.org/2001/XMLSchema#string

Laura Tipton

http://www.w3.org/2001/XMLSchema#string

Myrlene A Staten

http://www.w3.org/2001/XMLSchema#string

Steven E Shoelson

http://www.w3.org/2001/XMLSchema#string

Targeting Inflammation Using Salsalate in Type 2 Diabetes Study Team

http://www.w3.org/2001/XMLSchema#string

Vivian Fonseca

http://www.w3.org/2001/XMLSchema#string

Yii-Der Ida Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Inflammation and insulin resistance

The ancient drug salicylate directly activates AMP-activated protein kinase

The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase

A new pharmacological effect of salicylates: inhibition of NFAT-dependent transcription

Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta

Aspirin inhibits serine phosphorylation of insulin receptor substrate 1 in tumor necrosis factor-treated cells through targeting multiple serine kinases

Salicylate downregulates 11β-HSD1 expression in adipose tissue in obese mice and in humans, mediating insulin sensitization

Inhibition of NF-kappa B by sodium salicylate and aspirin

Type 2 diabetes as an inflammatory disease

The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta

P304

1-12

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7326/0003-4819-159-1-201307020-00003

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

159

http://www.w3.org/2001/XMLSchema#string

P50

Allison B Goldfine

P577

2013-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23817699

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

4128629

http://www.w3.org/2001/XMLSchema#string